Genetic PredispositionNCT07332598
Mayo Clinic Precure - Prospective Study
An observational study of Genetic Predisposition and Exposure, Environmental, run by Mayo Clinic at 1 site in United States.
Trial summary
The goal of this observational study is to 1) better understand and predict biological processes before disease begins or is identified, 2) study genomic and environmental contributors to disease, 3) identify ways to stop disease advancement before it becomes serious or complex, and 4) identify potential targets for… Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Genetic Predisposition, Exposure, Environmental
- How many people
- 100,000 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Jan 2026to Dec 2035
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Mayo Clinic patients
Who may be able to join
- Age ≥ 18 years
- Registered Mayo Clinic patient
- Able to provide informed written consent
- Able to receive mail and packages within a United States (US) state
- Able to collect and ship samples within a US state via FedEx for overnight delivery
Who cannot join
- Active hematological cancer or history of a hematological cancer
- Allogeneic Bone Marrow Transplant (autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
- Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
About this study
The goal of this observational study is to 1) better understand and predict biological processes before disease begins or is identified, 2) study genomic and environmental contributors to disease, 3) identify ways to stop disease advancement before it becomes serious or complex, and 4) identify potential targets for disease therapy.
Participants will be asked to:
- collect biological samples,
- download a mobile app,
- collect speech (voice) recordings, and
- complete surveys
- Conditions
- Genetic Predisposition, Exposure, Environmental
- Medical subject headings
- Genetic Predisposition to Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Suspected Genetic Predisposition or Multi-Omics Contribution | Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution | |
| Health Control | Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Build a comprehensive, multi-omics and phenotype dataset
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Jan 2026
- Study start19 Jan 2026
- Primary completionDec 2030 (estimated)
- Study completionDec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Genetic PredispositionStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 100,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Konstantinos N. Lazaridis, M.D., Mayo Clinic
- Investigators
- Konstantinos N. Lazaridis, M.D., Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07332598
- Sponsor's protocol ID
- 25-005869
- Status last verified
- Feb 2026
- First submitted
- 30 Dec 2025
- Last updated
- 16 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Thomas DC. High-volume "-omics" technologies and the future of molecular epidemiology. Epidemiology. 2006 Sep;17(5):490-1. doi: 10.1097/01.ede.0000229950.29674.68. No abstract available.
PubMed 16906051Ramos RG, Olden K. Gene-environment interactions in the development of complex disease phenotypes. Int J Environ Res Public Health. 2008 Mar;5(1):4-11. doi: 10.3390/ijerph5010004.
PubMed 18441400Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50. doi: 10.1158/1055-9965.EPI-05-0456. No abstract available.
PubMed 16103423
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mayo Clinic Precure - Prospective Study
- ClinicalTrials.gov ID
- NCT07332598
- Acronym / sponsor ID
- 25-005869
- Conditions
- Genetic Predisposition, Exposure, Environmental
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 100,000 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 19 Jan 2026 (actual)
- Primary completion
- Dec 2030 (estimated)
- Study completion
- Dec 2035 (estimated)
- First posted
- 12 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to 1) better understand and predict biological processes before disease begins or is identified, 2) study genomic and environmental contributors to disease, 3) identify ways to stop disease advancement before it becomes serious or complex, and 4) identify potential targets for disease therapy.
Participants will be asked to:
- collect biological samples,
- download a mobile app,
- collect speech (voice) recordings, and
- complete surveys
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Suspected Genetic Predisposition or Multi-Omics Contribution | – | –Patients with a diagnosis or phenotype with the potential for association with a genetic predisposition or Multi-Omics Contribution |
| Health Control | – | –Patients with no diagnosis associated with a genetic predisposition or Multi-Omics Contribution. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Mayo Clinic patients
Key inclusion criteria (5 listed)
- Age ≥ 18 years
- Registered Mayo Clinic patient
- Able to provide informed written consent
- Able to receive mail and packages within a United States (US) state
- Able to collect and ship samples within a US state via FedEx for overnight delivery
Key exclusion criteria (3 listed)
- Active hematological cancer or history of a hematological cancer
- Allogeneic Bone Marrow Transplant (autologous bone marrow transplant recipients are acceptable if collected at least one month after transplant)
- Other co-morbidity that, in physician's opinion, would interfere with patient's ability to participate in the study (e.g., reduced ability to comprehend, i.e., dementia, intellectual disability, etc.)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Build a comprehensive, multi-omics and phenotype dataset
Time frame: Up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2026.
- Background: PubMed 16906051Thomas DC. High-volume "-omics" technologies and the future of molecular epidemiology. Epidemiology. 2006 Sep;17(5):490-1. doi: 10.1097/01.ede.0000229950.29674.68. No abstract available.
- Background: PubMed 18441400Ramos RG, Olden K. Gene-environment interactions in the development of complex disease phenotypes. Int J Environ Res Public Health. 2008 Mar;5(1):4-11. doi: 10.3390/ijerph5010004.
- Background: PubMed 16103423Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1847-50. doi: 10.1158/1055-9965.EPI-05-0456. No abstract available.
- Individual participant dataSharing planned: Undecided
Related trials for Genetic Predisposition
Enrolling by invitationObservational study
Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders
Primary Immunodeficiency, DOCK8
Active, not recruitingObservational study
Genetic Polymorphism Associated With Coronary Heart Disease Susceptibility and Variability of Clopidogrel Response
Coronary Disease
RecruitingObservational study
Vascular Disease Discovery Protocol
Vascular Dysfunction, Genetic Mutations
RecruitingObservational study
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
Kidney Neoplasms, Kidney Cancer
RecruitingObservational study
Rare Tumors and Cancer Predisposition in Individuals and Families
Cancer, Hereditary Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Konstantinos N. Lazaridis, M.D. principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Genetic Predisposition and Exposure, Environmental, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 16 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Build a comprehensive, multi-omics and phenotype dataset (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07332598, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2026.